Pneumococcal conjugate second or third-dose vaccines (PCVc) in Mauritius
Mauritius: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 98.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Mauritius, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Mauritius recorded 98.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
That represents a change of up 3.2% on the previous year and up 2.1% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Mauritius peaked at 98.0% in 2025 and was at its lowest, 0.0%, in 2008.
Mauritius ranks 11th of 194 countries on this measure, in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Mauritius, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 10.0% | — |
| 2017 | 84.0% | +740.0% |
| 2018 | 96.0% | +14.3% |
| 2019 | 97.0% | +1.0% |
| 2020 | 96.0% | -1.0% |
| 2021 | 93.0% | -3.1% |
| 2022 | 97.0% | +4.3% |
| 2023 | 91.0% | -6.2% |
| 2024 | 95.0% | +4.4% |
| 2025 | 98.0% | +3.2% |
Mauritius compared with similar countries
- Mauritius's 98.0% is above the median for upper middle income countries, which is 76.0%, 1.3× the median. (57 countries reporting)
- Mauritius's 98.0% is above the median for Sub-Saharan Africa, which is 82.5%, 1.2× the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 28.7% | 0.0% | 97.0% | 10 |
| 2020s | 95.0% | 91.0% | 98.0% | 6 |
Countries ranked near Mauritius
- 11 Turkmenistan 98.0% compare
- 11 El Salvador 98.0% compare
- 11 Portugal 98.0% compare
- 11 Costa Rica 98.0% compare
- 11 Saudi Arabia 98.0% compare
More health data for Mauritius
- Un projection of annual infant deaths, annual growth rate -10 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.0345 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 2,032 deaths per 1,000 people (2090)
- Number of infants who die before age 1 9 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.54 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0232 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.8573 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Mauritius?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Mauritius was 98.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Mauritius?
- The highest recorded value was 98.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Mauritius?
- The lowest recorded value was 0.0% in 2008.
- How does Mauritius rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Mauritius ranks 11th out of 194 countries with data for 2025.
- Where does this Mauritius data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).